A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF-06821497 (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

Most Recent Events

24 Oct 2019 Planned End Date changed from 25 Sep 2023 to 24 Dec 2023.
24 Oct 2019 Planned primary completion date changed from 25 Sep 2023 to 24 Dec 2023.
11 Aug 2019 Planned End Date changed from 15 Sep 2023 to 25 Sep 2023.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight